Phase I trial with a combination of docetaxel and 153Sm-lexidronam in patients with castration-resistant metastatic prostate cancer

This publication has 24 references indexed in Scilit:

• Phase I Study of Concurrent Weekly Docetaxel and Repeated Samarium-153 Lexidronam in Patients With Castration-Resistant Metastatic Prostate Cancer
  Journal of Clinical Oncology, 2009
• Phase I Study of Samarium-153 Lexidronam With Docetaxel in Castration-Resistant Metastatic Prostate Cancer
  Journal of Clinical Oncology, 2009
• Combining ¹⁵³ Sm-Lexidronam and Docetaxel for the Treatment of Patients with Hormone-Refractory Prostate Cancer: First Experience
  Cancer Biotherapy and Radiopharmaceuticals, 2008
• Impact of skeletal complications on patients’ quality of life, mobility, and functional independence
  Supportive Care in Cancer, 2008
• Current Trials Using Bone-Targeting Agents in Prostate Cancer
  The Cancer Journal, 2008
• Bone Directed Therapies for Prostate Cancer
  Journal of Urology, 2007
• A comparative study of 188Re-HEDP, 186Re-HEDP, 153Sm-EDTMP and 89Sr in the treatment of painful skeletal metastases
  Nuclear Medicine Communications, 2007
• Bone metastases in prostate cancer: a targeted approach
  Current Opinion in Oncology, 2007
• Safety and efficacy of repeat administration of samarium Sm‐153 lexidronam to patients with metastatic bone pain
  Cancer, 2006
• Docetaxel plus Prednisone or Mitoxantrone plus Prednisone for Advanced Prostate Cancer
  New England Journal of Medicine, 2004